Cary Street Partners Investment Advisory’s GSK GSK Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $45.1K | Buy |
1,176
+162
| +16% | +$6.22K | 0.02% | 408 |
|
|
2025
Q1 | $39.3K | Buy |
1,014
+852
| +526% | +$33K | 0.02% | 386 |
|
|
2024
Q4 | $5.48K | Sell |
162
-6,833
| -98% | -$231K | ﹤0.01% | 461 |
|
|
2024
Q3 | $286K | Sell |
6,995
-411
| -6% | -$16.8K | 0.01% | 638 |
|
|
2024
Q2 | $285K | Buy |
7,406
+2,344
| +46% | +$90.2K | 0.01% | 612 |
|
|
2024
Q1 | $217K | Sell |
5,062
-521
| -9% | -$22.3K | 0.01% | 651 |
|
|
2023
Q4 | $207K | Hold |
5,583
| – | – | 0.01% | 614 |
|
|
2023
Q3 | $202K | Buy |
5,583
+803
| +17% | +$29.1K | 0.01% | 553 |
|
|
2023
Q2 | $170K | Sell |
4,780
-160
| -3% | -$5.7K | 0.01% | 551 |
|
|
2023
Q1 | $176K | Sell |
4,940
-442
| -8% | -$15.7K | 0.01% | 494 |
|
|
2022
Q4 | $189K | Sell |
5,382
-847
| -14% | -$29.8K | 0.01% | 481 |
|
|
2022
Q3 | $183K | Buy |
6,229
+1,319
| +27% | +$38.8K | 0.02% | 458 |
|
|
2022
Q2 | $267K | Buy |
+4,910
| New | +$267K | 0.02% | 375 |
|
|
2021
Q1 | – | Sell |
-8,944
| Closed | -$411K | – | 363 |
|
|
2020
Q4 | $411K | Buy |
8,944
+5,558
| +164% | +$255K | 0.08% | 212 |
|
|
2020
Q3 | $159K | Buy |
+3,386
| New | +$159K | 0.03% | 296 |
|